Design and synthesis of novel protein kinase R (PKR) inhibitors

Sagiv Weintraub, Tali Yarnitzky, Shirin Kahremany, Iliana Barrera, Olga Viskind, Kobi Rosenblum, Masha Y. Niv, Arie Gruzman*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Protein kinase RNA-activated (PKR) plays an important role in a broad range of intracellular regulatory mechanisms and in the pathophysiology of many human diseases, including microbial and viral infections, cancer, diabetes and neurodegenerative disorders. Recently, several potent PKR inhibitors have been synthesized. However, the enzyme’s multifunctional character and a multitude of PKR downstream targets have prevented the successful transformation of such inhibitors into effective drugs. Thus, the need for additional PKR inhibitors remains. With the help of computer-aided drug-discovery tools, we designed and synthesized potential PKR inhibitors. Indeed, two compounds were found to inhibit recombinant PKR in pharmacologically relevant concentrations. One compound, 6-amino-3-methyl-2-oxo-N-phenyl-2,3-dihydro-1H-benzo[d]imidazole-1-carboxamide, also showed anti-apoptotic properties. The novel molecules diversify the existing pool of PKR inhibitors and provide a basis for the future development of compounds based on PKR signal transduction mechanism.

Original languageAmerican English
Pages (from-to)805-819
Number of pages15
JournalMolecular Diversity
Volume20
Issue number4
DOIs
StatePublished - 1 Nov 2016

Bibliographical note

Publisher Copyright:
© 2016, Springer International Publishing Switzerland.

Keywords

  • Benzoimidazole derivatives
  • C16
  • Computer modelling
  • PKR inhibitors

Fingerprint

Dive into the research topics of 'Design and synthesis of novel protein kinase R (PKR) inhibitors'. Together they form a unique fingerprint.

Cite this